Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79739.880.1262%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Autolus Therapeutics PLC

AUTLNASDAQ
Trade with Public
Trade with Public
$2.24
-0.05-2.18%
At close: Sep 4, 5:00 PM EST
$2.25
0.00960.43%
After Hours: Sep 4, 7:14 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Autolus Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Autolus Therapeutics (AUTL).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

8Buy
Consensus RatingBuy# Analysts8Avg. Consensus PT$9Upside to Avg. PT+306.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 3, 2026HC Wainwright & Co.Emily BodnarMaintainedBuy$10
May 14, 2026HC Wainwright & Co.Emily BodnarPT RaiseBuy$9→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Autolus Therapeutics, Raises Price Target to $10

HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $9 to $10.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10

Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowers the price target from $12 to $10.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Initiates Coverage On Autolus Therapeutics with Buy Rating, Announces Price Target of $9

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $9.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved